<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02137954</url>
  </required_header>
  <id_info>
    <org_study_id>2013-50</org_study_id>
    <nct_id>NCT02137954</nct_id>
  </id_info>
  <brief_title>Efficacy of Lidocaine Versus Placebo in Palliative Care Patients With Opioid-refractory Cancer Pain With Neuropathic Component: a Multicenter, Prospective, Double-blind Randomized Placebo-controlled Study.</brief_title>
  <acronym>LIDOSP</acronym>
  <official_title>Efficacy of Lidocaine Versus Placebo in Palliative Care Patients With Opioid-refractory Cancer Pain With Neuropathic Component: a Multicenter, Prospective, Double-blind Randomized Placebo-controlled Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, prospective, randomized, placebo-controlled, double-blind,
      two-parallel groups study comparing lidocaine (experimental group) to placebo (control
      group). The study protocol was elaborated using the recommendations of the Consolidated
      Standards of Reporting Trials (CONSORT) Statement.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Analgesic efficacy</measure>
    <time_frame>40 minutes</time_frame>
    <description>Analgesic efficacy will be assessed from several endpoints. The primary endpoint will be defined as the change of pain level between baseline (T0) and 40 minutes (T1) after baseline. The pain level will be assessed using a self-administered numeric pain intensity scale (NPIS), ranged from 0 (no pain) to 10 (worst pain possible). A minimal 30% decrease of pain level between baseline and T1 will define the success, and other cases will define the failure of the treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>intensity of the pain neuropathic</measure>
    <time_frame>120 minutes</time_frame>
    <description>the intensity of the pain neuropathic component using the Neuropathic Pain Symptom Inventory (NPSI) at T4, T5, and T6 {Bouhassira, 2004 #9}; the NPSI is a 12-item self-administered questionnaire describing the intensity of the symptoms associated with pain neuropathic</description>
  </secondary_outcome>
  <other_outcome>
    <measure>raw values of pain levels (NPIS)</measure>
    <time_frame>40 minutes</time_frame>
    <description>raw values of pain levels (NPIS) at each evaluation time, percentage of reduction between the initial level of pain and other evaluation times</description>
  </other_outcome>
  <other_outcome>
    <measure>tolerance to the treatments</measure>
    <time_frame>48 hours</time_frame>
    <description>The tolerance to the treatment (lidocaine) will be assessed during the first 48 hours following the treatment administration. Adverse events will be cautiously collected (intensity and discomfort): i) lidocaine: arrhythmia, blurred vision, headache, malaise, tremors, metallic taste, nausea/vomiting, perioral numbness and tingling, sedation, and tinnitus.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Cancer</condition>
  <condition>Pain With Neuropathic Component</condition>
  <arm_group>
    <arm_group_label>lidocaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lidocaine. Initial dose IV will be 5 mg/kg per day during the first 24 hours the 8 mg/kg per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <arm_group_label>lidocaine</arm_group_label>
    <other_name>Lidocaine. Initial dose IV will be 5 mg/kg per day during the first 24 hours the 8 mg/kg per day</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient aged 18 years or older

          -  Patient suffering from cancer pain refractory to standard opiates (numeric pain
             intensity scale NPIS &gt;=4/10 after 24 hours of continuous intravenous morphine or
             oxycodone administration [SOR 2002, analgesics drugs for adults cancer nociceptive
             pain]), regardless of the nature of the primary cancer]

          -  Patient suffering from cancer neuropathic or mixed pain (DNA survey score&gt; = 4
             [Bouhassira 2004])

          -  Patient receiving palliative care as defined by French Society of Palliative and
             Support Care [Charte des Soins Palliatifs, 1996, Act No. 99-477 of 9 June 1999 to
             guarantee the right of access to palliative care] according to the definition of the
             World Health Organization (WHO) [World Health Organization. WHO's pain ladder.
             http://www.who.int/cancer/palliative/painladder/en/. Accessed December 9.2011]

          -  Patient with histological diagnosis of cancer, locally advanced or metastatic disease

          -  Patient without curative cancer treatment, and with or without palliative anticancer
             treatment

          -  Patient hospitalized in a specific palliative care unit

          -  Patient with an estimated survival higher than 48 hours (physician estimation) Patient
             providing written informed consent for participation prior to any study procedures.

        Exclusion Criteria:

          -  Patient with a known hypersensitivity to lidocaine

          -  Patient with a history of porphyria, arrhythmias, disorders of atrioventricular
             conduction requiring permanent pacing not yet realized, uncontrolled epilepsy,
             uncontrolled hypertension

          -  Patient with hematologic malignancy, abnormal renal, hepatic and cardiac functions

          -  Patient with a altered sleepiness (Epworth scale score ≤ 16)

          -  Patient with altered cognitive function (TELECOM scale score&gt; 11) [Arsène 2000]

          -  Patient not native French speaker Patient defined as vulnerable subject (minor
             subject, pregnant or nursing woman, subject freedom deprived)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sebastien SALAS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>- Service d'Oncologie Médicale et de Soins Palliatifs Assistance Publique Hopitaux de Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sebastien SALAS, MD</last_name>
    <phone>+33491384408</phone>
    <email>sebastien.salas@ap-hm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>- Service d'Oncologie Médicale et de Soins Palliatifs Assistance Publique Hopitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastien Salas, MD</last_name>
      <phone>+3349138408</phone>
      <email>sebastien.salas@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>sebastien salas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2014</study_first_submitted>
  <study_first_submitted_qc>May 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2014</study_first_posted>
  <last_update_submitted>August 27, 2015</last_update_submitted>
  <last_update_submitted_qc>August 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cancer Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

